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Background: Low-grade fibromyxoid sarcoma (LGFMS) is a rare soft tissue tumor typically affecting young to
middle-aged adults. Despite its otherwise benign histologic appearance and indolent nature, it can have fully
malignant behavior, and recurrence and metastasis may occur even decades later.
Case history: We report a case of LGFMS in the left lower leg of a 5-year-old Japanese boy. A magnetic resonance
imaging (MRI) uncovered a well-demarcated intra-gastrocnemial tumor measuring 27 × 20 mm with a slightly high
intensity on T1WI and heterogeneously high intensity on T2WI. Histologically, the tumor was composed of bland
spindle-shaped cells with a whorled growth pattern. The tumor stroma was variably hyalinized and fibromyxoid
with arcades of curvilinear capillaries and arterioles with associated perivascular fibrosis. Although LGFMS is known
to affect children under 18 years of age, it is extremely rare in infants and children under 5 years of age. Despite
the young age, this patient was accurately diagnosed by the typical histology and the detection of a FUS-CREB3L2
gene fusion.
Conclusion: Although LGFMS in children tends to be located superficially, this case presented with an intramuscular
tumor in the region of the gastrocnemius. To the best of our knowledge, this is the first case of deep LGFMS arising in
a child younger than 5 years of age. The patient is still alive with no evidence of the disease 4 months after diagnosis.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
13000_2014_163
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Low-grade fibromyxoid sarcoma (LGFMS) is a rare soft
tissue tumor that typically affects young to middle-aged
adults [1,2]. The median age of onset for LGFMS is
34 years [3], although patients of any age can be af-
fected, and 13-19% of cases occur in patients 18 years
and younger [3,4]. However, LGFMS is rare in children
during the first 5 years of life [2]. To the best of our
knowledge, the youngest case of LGFMS is a tumor aris-
ing from the cheek in a 22-month-old girl [4]. Histologi-
cally, LGFMS is composed of bland spindle-shaped cells* Correspondence: tysaitou@juntendo.ac.jp
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article, unless otherwise stated.in a whorled growth pattern, arranged in alternating
myxoid and collagenized areas along with curvilinear ca-
pillaries and characteristic arterioles with perivascular fi-
brosis. Although most of the tumor cells show benign
histological appearance, approximately 10% of the tumor
may have scattered large, hyperchromatic and pleo-
morphic nuclei [1]. Furthermore, approximately 40% of
cases have focal areas of hypocellular collagen cores
rimmed by epithelioid fibroblasts, referred to as collagen
pseudo-rosettes. Cases with prominent collagen pseudo-
rosettes are referred to as hyalinizing spindle cell tumor
with giant rosettes [5].
In spite of its otherwise benign histologic appearance
and indolent progression, many cases of the LGFMS
may recur or metastasize decades later, mainly to thed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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http://www.diagnosticpathology.org/content/9/1/163lung. Therefore, it is important to make a correct diagno-
sis and provide long-term follow-up for LGFMS patients.
However, a diagnosis of LGFMS is often difficult because
of a small biopsy specimen that can lead to a misdiagnosis
of malignant tumors as benign or as tumor-like lesions
including nodular fasciitis, schwannoma, desmoid-type
fibromatosis, neurofibroma, and myxofibrosarcoma [6-8].
Although, LGFMS is negative for most immunohisto-
chemical markers, a recent study identified up-regulation
of the mucin 4 (MUC4) gene in LGFMS compared with
histologically similar tumors and lesions [8,9], and MUC4
immunostaining was a sensitive and specific marker of
LGFMS in the appropriate morphologic context [2,5].
Additionally, it has been described that claudin-1, which
was associated with tight junction protein, and epithelial
membrane antigen (EMA) were negative for LGFMS [10]
with exceptional positivity for LGFMS with perineurioma-
tous component [11]. Perineurioma is a benign soft tissue
tumor, derived from perineural cells which differ from
other mesenchymal cells by virtue of their formation of
tight junctions [10].
Several recent studies demonstrated that greater than
90% of LGFMS have a balanced chromosomal translocation
t (7;16) (q32-34;p11) leading to the fusion of the FUS and
CREB3L2, while a minority of cases have a t(11;16) (p11;
p11) translocation leading to the fusion of the FUS and
CREB3L1 [1,2,5-7,12,13]. In one report, a small number of
LGFMS cases contained EWSR-CREB3L1 gene fusions [5].
We report a case of a 5-year-old Japanese boy with
deeply located LGFMS in the lateral aspect of the lower
leg. The diagnosis of LGFMS was confirmed by the pres-
ence of the characteristic FUS-CREB3L2 gene fusion using
reverse transcription polymerase chain reaction (RT-PCR)
from a formalin-fixed, paraffin-embedded (FFPE) biopsy
specimen.Figure 1 MRI of lower left leg of the 5-year-old patient. An axial view
aspect of the gastrocnemius. The mass had slightly high intensity compare
intensity on T2WI (B).Case presentation
A 5-year-old Japanese boy was referred to our hospital with
a painless mass in the lateral aspect of the left lower leg.
An MRI revealed a well-demarcated intra-gastrocnemial
tumor measuring 20 × 27 mm with slightly high intensity
on T1WI and heterogeneously high intensity on T2WI
(Figures 1A and 1B). Histopathologically, the tumor was
composed of bland spindle-shaped cells with a whorled
growth pattern on the biopsy specimen. The tumor stroma
was variably hyalinized and fibromyxoid with arcades
of curvilinear capillaries and arterioles with perivascular
fibrosis (Figure 2A-2C). The tumor showed no nuclear
pleomorphism, high cellularity, or necrosis, and had few
mitoses. Differential diagnosis on conventional H&E stain-
ing included desmoid-type fibromatosis, schwannoma,
and LGFMS. Immunohistochemically, the tumor cells were
negative for S-100 protein and nuclear staining of beta-
catenin, typically present in desmoid-type fibromatosis.
The Ki67 proliferation index was approximately 20%
(Figure 2D and 2E). Moreover, we performed immunohis-
tochemical staining for MUC4 (sc-53945, Santa-Cruz
Biotechnology, Dallas, TX, 1:100, mouse monoclonal),
claudin-1 (Product# LS-B6327, LifeSpan Biosciences, Se-
attle, WA, 1:200, rabbit polyclonal) and EMA (E29, DAKO,
Grostrup, Denmark, 1:100, mouse, monoclonal) on this
case. Tumor cells showed diffuse, strong cytoplasmic
immunoreactivity for MUC4. On the other hand, the
tumor did not show immunoreactivity for claudin-1 and
EMA in line with the absence of perineuriomatous compo-
nent (Figure 2F and 2G).
To determine if the FUS-CREB3L1 and FUS-CREB3L2
fusion genes were present in the tumor, we performed
RT-PCR from FFPE tumor tissue. Briefly, five 10-μm
thick paraffin sections were cut from the paraffin-
embedded block. RNA was isolated using the RNeasyMRI revealed a well-defined mass measuring 27 × 20 mm in the lateral
d to the skeletal muscle on T1WI (A) and a heterogeneously high
Figure 2 Tumor Histology. An admixture of myxoid and fibrous areas was observed on H&E staining (A). Higher magnification views of myxoid
(B) and fibrous (C) components of the tumor. A whorled growth pattern with bland spindle-shaped tumor cells was observed. Immunoreactivity
for nuclear β-catenin was absent (D). Ki67 staining was present with a proliferative index of approximately 20% (E). Tumor cells showed diffuse
and strong immunoreactivity for MUC4 (F). Tumor was negative for claudin-1 (G).
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Figure 3 Detection of a FUS-CREB3L2 fusion in the LGFMS tumor. RT-PCR on FFPE-derived RNA was performed. DNA sequencing revealed a
fusion between FUS exon 6 and CREB3L2 exon 5.
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was reverse transcribed to cDNA using the Superscript
first-strand synthesis system for RT-PCR (Invitrogen,
CA, USA). The primer sequences used for the amplifica-
tion in this study were described previously [14]. The
PCR product was separated on a 2% agarose gel, and a
PCR product of the appropriate size was cut from the
gel and sequenced. Sequencing confirmed a gene fusion
between exon 6 of the FUS and exon 5 of CREB3L2
(Figure 3). Despite the young age of the patient, a diag-
nosis of LGFMS was confirmed, and the patient subse-
quently underwent wide resection at the affected area.
Macroscopically, the resected surface of the surgical spe-
cimen was gray with a glistening appearance (Figure 4).
Pathological analysis of the resected tumor confirmed
the LGFMS histology observed in the biopsy specimen.
Four months after diagnosis, the patient is alive with no
evidence of the disease.
Discussion
The importance of molecular pathological diagnosis is
increasing in the clinical pathology, especially in the field
of soft tissue sarcomas, because the definite diagnosis
made by the molecular pathology such as RT-PCR and
specific genetic testing sometimes leads to the applica-
tion of the tumor specific therapy [15-17]. Recently,Figure 4 Gross morphology of LGFMS from the 5-year-old patient.
The resected surface of intramuscular tumor is tan to gray colored and
has a glistening appearance. The tumor is located in the subcutis and
skeletal muscle throughout the fascia.LGFMS was shown to be associated with gene fusions
involving CREB3-family genes that encode members of
the basic leucine zipper family of transcription factors
[2]. The majority of LGFMS cases (95%) have a fusion
of the FUS-CREB3L2, and a minority of cases (5%) have
a FUS-CREB3L1 gene fusion. In addition, a small num-
ber of cases have EWSR-CREB3L1 gene fusions [5]. Be-
cause of its typical histology and the presence of a
FUS-CREB3L2 fusion, we were able to correctly diag-
nose LGFMS, despite the atypical age of the patient.
LGFMS can affect patients of all ages, and 13-19% of
the cases occur in patients younger than 18 years of age
[3,4]. Nonetheless, desmoid-type fibromatosis would be
the most important differential diagnosis in this deeply lo-
cated tumor. Desmoid-type fibromatosis is a locally ag-
gressive infiltrative intra-muscular tumor, in spite of
benign histologic feature. Frequent recurrences can be
clinically observed even after wide resection. A “wait-and-
see” strategy is, at the present time, preferred in case of
asymptomatic or non-progressive disease, especially for
the patients of young age. Medical treatment such as
cyclooxygenase-2 selective inhibitor is another choice for
the patients with desmoid-type fibromatosis [18].
LGFMS is extremely rare in children younger than
5 years of age [2], and we found only 34 LGFMS cases
in children under 15 years of age reported in English lit-
eratures. The clinical, histological, and genetic informa-
tion of the previously reported cases are summarized in
Table 1 [1,2,4-7,12,13,19-27]. Nine cases up to 5 years of
age were found including the present case. In our review
of LGFMS in infants and young adolescents, the male to
female ratio was 7:2 in infants (0-5 years of age) and 8:5
in young adolescents (6-15 years of age). In adult cases,
the male to female ratio was reported to be either equal
[7] or 3:1 [28]. The greatest mean tumor diameter was
3.7 cm in both infants and young adolescents, and this
was smaller than that found in adult cases (mean
7.7 cm) [4]. LGFMS tends to be located superficially in
young patients, whereas deep LGFMS accounts for the
majority of adult cases [1,7]. Superficial LGFMS was re-
ported to account for no more than 10% of LGFMS
cases in all ages [4]; however, it was found in 73% of the
Table 1 Literature review of LGFMS of children (≦15 y. o.)
Case Age Sex Site Location Size Genetic abnormality Characteristicfeature Recurrence Reference









3 14 M brachium subfascial φ50mm (−) [6]
4 14 M brachium subfascial φ30mm FUS gene rearrangement
(+) by FISH
[6]
5 6 M Lower leg subcutis φ10mm EWSR1 (Ex9)/ CREB3L1 (Ex5)
fusion gene by RT-PCR
(−) [5]
6 13 M popliteal fossa deep
FUS/ CREB3L1 fusion gene
by array-CGH
(−) [12]
7 3 M thigh subcutis 17 × 16 × 12 mm
FUS gene rearrangement
(+) by FISH and
unusual histology+








9 6 F inguinal area φ35mm recurrence 5 times, meta
for lung 39 years later
[19]
10 9 M neck
recurrence 7 times,
meta 16 years later
[19]
11 6 M deltoid φ33mm (−) [19]
12 10 F leg with giant rosettes [20]
13 13 F back (−) at 36mos [20]
14 1.8 M cheek φ80mm (−) 6mo [4]
15 13 F arm φ30mm FUS (Ex6)/ CREB3L2 (Ex5)
fusion gene by RT-PCR
(−) at 34mos [21]
16 11 M axilla φ60mm FUS (Ex6)/ CREB3L2 (Ex5)
fusion gene by RT-PCR
[21]
17 15 M thorax φ30mm FUS (Ex6)/ CREB3L1 (Ex5)
fusion gene by RT-PCR
[21]
18 13 M foot φ60mm FUS (Ex6)/ CREB3L2 (Ex5)
fusion gene by RT-PCR





















Table 1 Literature review of LGFMS of children (≦15 y. o.) (Continued)
19 13 F abdominal wall intramuscular
FUS (Ex6)/ CREB3L2 (Ex5)
fusion gene by RT-PCR
[13]




superficial φ42mm (−) at 60mos [22]
22 5 M knee superficial φ40mm (−) at 48mos [22]
23 6 M superficial φ20mm lost to follow up [22]
24 8 M back superficial φ30mm local recurrence at 16mos,
then lost to follow up
[22]
25 10 F lower leg superficial φ16mm (−) at 48mos [22]
26 13 M fore arm superficial (−) at 60mos [22]
27 13 F thigh
FUS (Ex6)-insertion-CREB3L2
(Ex5) fusion gene by RT-PCR
local recurrence at 156,
192, 228, 252, 264, [23]
and 276 mos
28 12 F buttock φ30mm FUS (Ex6)/ CREB3L2 (Ex5)
fusion gene by RT-PCR
lost to follow up [23]
29 12 M foot φ30mm FUS (Ex6)/ CREB3L2 (Ex5)
fusion gene by RT-PCR
local recurrence at 19mos [23]
30 4 M paravertebral 90 × 80 × 60 mm with giant rosettes local recurrence at 3mos [24]
31 13 M buttock superficial
local recurrence at 24,
36, 60mos
[25]
32 11 F shoulder deep φ45mm (−) 34mos [25]
33 14 F inflaclavicular φ30mm (−) 58mos [26]
34 4 M thigh φ30mm
local recurrence at 6,
36, and 84mos
[27]
lung metastasis at 36,
84, and 98mos
this case 5 M Lower leg subfascial φ26mm FUS (Ex6)/ CREB3L2 (Ex5)
fusion gene by RT-PCR
(−) at 4 mos
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line with the previous finding [22]. Particularly, in pa-
tients 5 years of age or younger in which information for
the depth of the tumor was available, all cases were lo-
cated superficially, and our case was the only one that
was deeply located.
Considering both the smaller size and superficial loca-
tion of LGFMS arising in correspondingly smaller in-
fants and young adolescents, LGFMS in children might
be noticed before becoming larger and invading into the
fascia and skeletal muscles. Metastasis/local recurrence
rates were 13%/38% in infants and 24%/41% in young
adolescents, respectively, in our literature review. These
rates are not significantly different from those previously
reported in adult LGFMS [19]. In addition, no differ-
ences in gene fusion events were noted between infants
and young adolescents with LGFMS.
Finally, we report a rare case of a 5-year-old Japanese
boy with deeply located LGFMS in the lateral aspect of
the lower leg. The superficial location of LGFMS in
pediatric patients might be a reason for the relatively
small tumor size in juvenile populations. Furthermore,
superficial tumors are easily palpable and readily recog-
nized by the patients and their parents.Conclusions
Wide resection of the tumor in the limb reduces the re-
currence rate, but also affecting the future functional
outcome, especially in the childhood. Recent advance in
molecular pathology is helpful to distinguish specific soft
tissue tumors from their histologic mimics. It is import-
ant to avoid misdiagnosis and provide appropriate treat-
ment with a help of molecular diagnosis.Consent
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